Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21.55 USD | +0.14% |
|
-.--% | +124.25% |
04/06 | Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete | MT |
04/06 | Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index | CI |
Sales 2022 | 1.46 121.97 | Sales 2023 | 2.07 172.65 | Capitalization | 70Cr 5.81TCr |
---|---|---|---|---|---|
Net income 2022 | -8.7Cr -726.33Cr | Net income 2023 | -9.4Cr -784.77Cr | EV / Sales 2022 | 71,05,352 x |
Net cash position 2022 | 13Cr 1.09TCr | Net cash position 2023 | 18Cr 1.53TCr | EV / Sales 2023 | 24,78,44,353 x |
P/E ratio 2022 |
-1.57
x | P/E ratio 2023 |
-6.64
x | Employees | 101 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
Latest transcript on FUSN PHAR
1 day | +0.14% | ||
3 months | +0.98% | ||
6 months | +172.78% | ||
Current year | +124.25% |
![Extreme 7.59](/images/extremecours_fleche.png)
![Extreme 2.31](/images/extremecours_fleche.png)
![Extreme 1.98](/images/extremecours_fleche.png)
![Extreme 1.98](/images/extremecours_fleche.png)
![Extreme 1.98](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Eric Burak
CTO | Chief Tech/Sci/R&D Officer | - | 01/17/01 |
Dmitri Bobilev
CTO | Chief Tech/Sci/R&D Officer | - | 07/22/07 |
Chief Tech/Sci/R&D Officer | 57 | 02/21/02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 4 M€ | -5.15% | - |
- Stock Market
- Equities
- FUSN Stock